David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
PUT
Transocean
RIG
$6.33B
| $15.6M | 0.02% |
1,789,900
+195,600
| +12% | +$1.68M |
|
827
CALL
Five Below
FIVE
$14.3B
| $15.5M | 0.02% |
125,000
+33,300
| +36% | +$4.03M |
|
828
CALL
CVS Health
CVS
$119B
| $15.5M | 0.02% |
287,400
-16,050
| -5% | -$991K |
|
829
COPT Defense Properties
CDP
$4.25B
| $15.5M | 0.02% |
566,930
-408,409
| -42% | -$10.3M |
|
|
AXE
830
DELISTED
Anixter International Inc
AXE
| $15.4M | 0.02% |
274,711
+27,802
| +11% | +$1.62M |
|
831
CALL
Medtronic
MDT
$117B
| $15.4M | 0.02% |
+169,000
| New | +$15.1M |
|
832
Melco Resorts & Entertainment
MLCO
$2.06B
| $15.4M | 0.02% |
681,380
-696,263
| -51% | -$15.1M |
|
833
CALL
Credit Acceptance
CACC
$6.26B
| $15.4M | 0.02% |
34,000
-26,500
| -44% | -$11.4M |
|
834
Teradata
TDC
$2.55B
| $15.3M | 0.02% |
349,590
-322,939
| -48% | -$14.5M |
|
|
CSII
835
DELISTED
Cardiovascular Systems, Inc.
CSII
| $15.2M | 0.02% |
393,613
-442,980
| -53% | -$15M |
|
836
CAE Inc
CAE
$8.07B
| $15.2M | 0.02% |
685,069
+371,300
| +118% | +$7.77M |
|
|
837
Credit Acceptance
CACC
$6.26B
| $15.2M | 0.02% |
33,606
-16,475
| -33% | -$7.09M |
|
|
EQC
838
DELISTED
Equity Commonwealth
EQC
| $15.2M | 0.02% |
463,869
+92,430
| +25% | +$2.96M |
|
839
CALL
Arista Networks
ANET
$242B
| $15.1M | 0.02% |
769,600
-427,200
| -36% | -$6.78M |
|
840
Workiva
WK
$4.01B
| $15.1M | 0.02% |
298,323
+169,443
| +131% | +$7.45M |
|
841
PUT
Union Pacific
UNP
$183B
| $15.1M | 0.02% |
+90,400
| New | +$14.5M |
|
|
RTN
842
PUT
DELISTED
Raytheon Company
RTN
| $15.1M | 0.02% |
82,800
+66,700
| +414% | +$11.6M |
|
843
CALL
American Tower
AMT
$82.7B
| $15.1M | 0.02% |
76,500
+7,600
| +11% | +$1.33M |
|
|
IRBT
844
CALL
DELISTED
iRobot
IRBT
| $15.1M | 0.02% |
128,000
+57,300
| +81% | +$6.1M |
|
845
CALL
Bausch Health
BHC
$2.48B
| $15.1M | 0.02% |
609,500
-435,500
| -42% | -$10.4M |
|
846
Dillards
DDS
$9.91B
| $15M | 0.02% |
208,270
+166,991
| +405% | +$11.5M |
|
|
GCP
847
DELISTED
GCP Applied Technologies Inc.
GCP
| $15M | 0.02% |
506,216
+181,072
| +56% | +$4.87M |
|
848
GATX Corp
GATX
$6.28B
| $15M | 0.02% |
196,164
+127,982
| +188% | +$9.57M |
|
849
AutoNation
AN
$6.37B
| $14.9M | 0.02% |
418,217
+386,453
| +1,217% | +$14M |
|
850
CALL
General Dynamics
GD
$102B
| $14.9M | 0.02% |
88,100
-11,400
| -11% | -$1.92M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.